interview Archives - Page 5 of 13

Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

By Lisa Cui 2024.01.15

Antimicrobial susceptibility testing (AST) is pivotal in both individualized and empirical treatments. Notably, standards set for interpreting AST results enable clinicians to choose suitable medications and optimal treatment plans, acting as a significant tool in controlling antimicrobial resistance. The most influential bodies in this space are the Clinical and Laboratory Standards Institute (CLSI) of the United States and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). These entities aim to standardize AST procedures and reduce experimental errors.

Interview with Chao Zhuo at ECCMID 2023

By El Bachir MOURABIT 2024.01.15

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) took place in Copenhagen, Denmark, from April 15th to 18th, 2023. As one of the most significant conferences in the field of clinical microbiology and infectious diseases, it marked a significant gathering after a three-year hiatus due to the pandemic. Chinese experts, including Dr. Chao Zhuo from The First Affiliated Hospital of Guangzhou Medical University, were present to share their insights.

Dr. Heather-Marie Schmidt: WHO Long-Acting PrEP Guidelines and Priority Actions to End HIV Epidemic in Asia

By Mourabit Halima 2024.01.15

Heather-Marie Schmidt BMedSc (Hon), MPH, PhD Dr. Schmidt serves as the Regional Advisor on HIV Testing, Prevention, and Key Populations for the Joint United Nations Programme on HIV/AIDS (UNAIDS) Asia-Pacific Regional Office and the World Health Organization (WHO) Global HIV, Hepatitis, and Sexually Transmitted Infections Program. She is dedicated to developing global guidelines for PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis) and providing technical assistance to countries, organizations, and communities in the Asia-Pacific region to support the implementation and promotion of PrEP.

Dr. Iskandar Azwa: Second and Third-Line Treatment Options for HIV/AIDS Patients

By Peter W. PENG 2024.01.15

Dr. Iskandar Azwa Chairman of the Malaysian AIDS Council, Head of Infectious Diseases Department at the University of Malaya Medical Center. His research interests include pre-exposure prophylaxis (PrEP) implementation in key populations, HIV drug resistance, and evaluating new HIV treatment strategies. He is the principal investigator for several international collaborative HIV clinical trials, including TAHOD, START, and D2EFT studies. At the APACC 2023 conference, Dr. Iskandar Azwa delivered an insightful presentation on "The Role of Nucleosides in Second-Line HIV Treatment." Our journal had the privilege to conduct an in-depth interview with Dr. Azwa regarding the choices for second and third-line treatment for HIV/AIDS patients.

Dr. Jennifer Hoy: How to Safely Transition ART in HIV Patients Achieving Viral Suppression?

By Mourabit Halima 2024.01.15

Infectious Disease/HIV Specialist and Medical Professor at Monash University Alfred Hospital, Australia. Member of the Australian Antiretroviral Guidelines Committee and the International Antiviral Society-USA (IAS-USA) Antiretroviral Guidelines Panel. Leading and participating in the development of new antiretroviral drugs and the prevention and management of opportunistic infections, with a primary research focus on complications related to aging in HIV-infected individuals and their pathogenesis, prevention, and management.

Dr. Dong Xu: Meeting More Patient Needs in HIV Health Management

By Mourabit Halima 2024.01.15

Implementation Science is a relatively new and increasingly recognized field of research. Its purpose is to translate the possibilities outlined in theory into practical applications in the real world, addressing the challenges of implementing validated intervention measures. At the 2023 APACC conference, Dr. Dong Hsu, from the School of Public Health Management and the Global Health Research Center, Southern Medical University, China, delivered an insightful presentation titled "Implementation of Clinical Practice Guidelines". In our interview, Dr. Dong Hsu further elaborated on the definition and research value of Implementation Science and shared his team's research findings in areas such as HIV screening and health management.

Dr. Reena Rajasuriar: Eliminating Regional Disparities to Achieve the 2030 End of HIV Epidemic

By Lisa Cui 2024.01.14

Co-President of APACC 2023, Chief Researcher at the Center of Excellence for HIV/AIDS Research (CERiA) at the University of Malaya, Associate Professor at the Faculty of Medicine, University of Malaya, Research Fellow at the Peter Doherty Institute for Infection and Immunity, University of Melbourne. She is primarily responsible for the University of Malaya's HIV Immunology Translational Research Program, with her current research focus on the immunopathogenic mechanisms of aging in HIV/AIDS patients and their impact on patient health.

Dr. Steven Grinspoon: Statin Drugs Can Be Used for Primary Prevention of Cardiovascular Diseases in HIV-Infected Individuals

By Mourabit Halima 2024.01.14

With the success of highly active antiretroviral therapy (HARRT), the life expectancy of HIV-infected individuals has significantly increased in recent years. The aging problem of HIV patients has become one of the main reasons affecting the quality of life and prognosis in the post-HARRT era. From July 23-26, 2023, the 12th International AIDS Society HIV Science Conference (IAS2023) was grandly held in Brisbane, Australia. At the conference, Dr. Grinspoon delivered an excellent report on primary prevention of cardiovascular diseases for PLWH. In this article, we have conducted an in-depth interview with Dr. Grinspoon. He shared insights on the metabolic and cardiovascular impacts related to PLWH treatments and the active role of statin drugs in preventing cardiovascular diseases in PLWH, especially as HIV treatment gradually shifts to chronic disease management.

Dr. Hongzhou Lu: NAD Management is Key for HIV Patients, Not Just Changing Medication

By Mourabit Halima 2024.01.14

The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.

Dr. Wei Cao: Focus on Managing HIV Complications, Further Improving Patient Survival

By Mourabit Halima 2024.01.14

The 12th International AIDS Society Conference on HIV Science (IAS 2023) was held from July 23-26, 2023, in Brisbane, Australia. As the largest open scientific conference in the global field of HIV/AIDS, it attracted the participation of experts, medical professionals, community organizations, and healthcare companies worldwide. Dr. Wei Cao from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was invited to attend the conference and was interviewed on-site by Infectious Disease Frontier. We have invited Dr. Cao to share the latest developments emerging from this conference and hot topics related to HIV/AIDS treatment.